It's going to be an exciting week for diabetes drug investors. The Food and Drug Administration has a two-day advisory panel lined up so that panelists can give their opinions on a pair of drugs.
First up is Bristol-Myers Squibb's
The FDA recently came down with stricter safety guidelines after it was discovered that GlaxoSmithKline's
Next up, on Thursday, is Novo Nordisk's
Keep your blood sugar under control, Fools; it's going to be an exciting week.
Our Foolishness is sweet: